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Abstract
Around two-thirds of all new HIV infections and 90% of syphilis cases occur in low- and
middle-income countries (LMICs). Testing is a key strategy for the prevention and treatment of HIV
and syphilis. Decision-makers in LMICs face considerable uncertainties about the costs of scaling
up HIV and syphilis testing. This paper synthesizes economic evidence on the costs of scaling up
HIV and syphilis testing interventions in LMICs and evidence on how costs change with the scale of
delivery. We systematically searched multiple databases (Medline, Econlit, Embase, EMCARE,
CINAHL, Global Health and the NHS Economic Evaluation Database) for peer-reviewed studies
examining the costs of scaling up HIV and syphilis testing in LMICs. Thirty-five eligible studies
were identified from 4869 unique citations. Most studies were conducted in Sub-Saharan Africa
(N¼17) and most explored the costs of rapid HIV in facilities targeted the general population
(N¼19). Only two studies focused on syphilis testing. Seventeen studies were cost analyses,
17 were cost-effectiveness analyses and 1 was cost–benefit analysis of HIV or syphilis testing.
Most studies took a modelling approach (N¼25) and assumed costs increased linearly with scale.
Ten studies examined cost efficiencies associated with scale, most reporting short-run economies
of scale. Important drivers of the costs of scaling up included testing uptake and the price of test
kits. The ‘true’ cost of scaling up testing is likely to be masked by the use of short-term decision
frameworks, linear unit-cost projections (i.e. multiplying an average cost by a factor reflecting
activity at a larger scale) and availability of health system capacity and infrastructure to supervise
and support scale up. Cost data need to be routinely collected alongside other monitoring
indicators as HIV and syphilis testing continues to be scaled up in LMICs.
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Introduction
HIV and syphilis infections are major public health problems world-
wide (Hook, 2017; Joint United Nations Programme on HIV/AIDS,
2018). In 2017, there were 1.8 million new HIV infections well
above the targets set by the World Health Organization (WHO) of
<500 000 new infections for HIV per year by 2020 (World Health
Organization, 2016; Joint United Nations Programme on HIV/
AIDS, 2018). In 2016, an estimated six million new cases of syphilis
were reported, far above the WHO target of <600 000 new infec-
tions for syphilis per year by 2030 (Joint United Nations Programme
on HIV/AIDS, 2018; World Health Organization, 2018). About
two-third of all new HIV infections and around 90% of syphilis
cases globally occur in low- and middle-income countries (LMICs)
(Newman et al., 2013; Joint United Nations Programme on HIV/
AIDS, 2018; World Bank, 2019). Untreated HIV and syphilis can
lead to mother-to-child transmission (MTCT), which in turn leads
to adverse maternal and neonatal outcomes (2018). The global
health community, led by the WHO, has identified the dual elimin-
ation of MTCT of HIV and syphilis as a public health priority
(World Health Organization, 2017a).
Epidemiologically, syphilis has been closely associated with HIV.
Both infections have a common route of transmission and syphilitic
genital ulcers provide a portal for HIV acquisition (Hook, 2017).
Research has long shown that early access to treatment can reduce
HIV- and syphilis-related deaths and prevent transmission (Sanders
et al., 2005; Bert et al., 2018). However, these benefits are only like-
ly to occur if individuals know their HIV/syphilis status. To facili-
tate early diagnosis, low-cost, easy to use and highly sensitive and
specific HIV and syphilis rapid tests are available (Storey et al.,
2019). By the end of 2017, only around 75% of people living with
HIV knew their status, and of those diagnosed positive, only 79%
received treatment globally (Joint United Nations Programme on
HIV/AIDS, 2018). The coverage of syphilis testing lags behind HIV
testing in many countries, especially among pregnant women and
other high-risk groups such as female sex workers (FSWs) and men
who have sex with men (MSM) (Kamb et al., 2010; UNICEF East
Asia and Pacific Regional Office, 2016). It has been estimated that,
in 2017, only 56% of pregnant women were tested for syphilis in
Africa and 31% in South-East Asia (World Health Organization,
2018). In 2019, 95% and 57% of pregnant women were tested
and treated for HIV in Eastern and Southern Africa and East Asia
and Pacific, respectively (UNICEF, 2020). Low testing uptake
has led to renewed commitments by national governments and
international agencies to scale up HIV and syphilis ‘test and treat’
strategies (Kamb et al., 2010; UNICEF East Asia and Pacific
Regional Office, 2016).
Scaling up, broadly defined as the ‘deliberate effort to increase
the impact of successfully tested health innovations, so as to benefit
more people’ (Simmons and Shiffman, 2007), has a direct impact on
costs. Scaling up decentralized tests, outside of laboratories, requires
multiple systems to be considered other than the test itself, such as
training, quality management, stock managing, reporting and these
need to be considered when calculating costs (Johns and Torres,
2005; Mabey et al., 2012). Major divergences have been reported
between the costs of HIV and syphilis testing observed in pilot or
small-scale studies relative to national roll-out (Johns, 2015; Shelley
et al., 2015; Bautista-Arredondo et al., 2018a). Empirical studies
have found that this has resulted from the exclusion or inaccurate
measurement of the unit costs of transport especially in rural and re-
mote areas, procurement and re-supply of test kits, recruiting and
training new staff and strengthening health system infrastructure
required for quality control and maintenance (Johns and Torres,
2005; Mikkelsen et al., 2017). Economies of scale also lead to
changes in the cost structure of programmes. Theories of economies
of scale suggest that the cost per unit decreases as more units are
produced (Getzen, 2014). This could be the result of fixed costs
being spread over more units of output, reducing per unit costs or
due to higher volumes that permit greater specialization of staff (e.g.
health facilities in less densely areas may not have enough patient
volume for a full-time testing counsellor). In contrast, variable
inputs such as test kits and supplies vary directly with the level of
output; the amount of fixed inputs cannot be changed in what econ-
omists refer to as the ‘short run’. In the short run, the limits of these
fixed inputs, whether they are buildings, testing equipment or staffs,
imply that further scale up is not possible or will create inefficien-
cies. In the long run, the fixed inputs are flexible and can be changed
to adapt to the different levels of activity, resulting in a non-linear
relationship between scale and cost and requiring analysis to distin-
guish between the short and long runs (Vita, 1990). These relation-
ships and the critical inputs to production will also be different
when scaling up services at a clinic to reach more individuals and
when scaling up from a single clinic to a national programme
(Gomez et al., 2020).
Interest in measuring economies in HIV and syphilis testing of
scale has risen with the development of rapid point of care tests
(Mabey et al., 2012; Storey et al., 2019). Unit costs of existing auto-
mated laboratory testing at a central laboratory may benefit from
economies of scale through the distribution of fixed costs, but these
costs do not take into account the need for multiple clinic visits, pa-
tient costs of accessing testing services and the failure of results to
reach patients due to the slow turnaround associated with these
tests. Rapid testing at or near the point of care has the potential for
savings to the patient through the quick delivery of results and to
Key Messages
• Scale is an important driver in determining the costs of HIV and syphilis testing programmes in resource-constrained
health systems
• Common methodological assumptions including short-run framework, linear unit cost projections and the availability of
health system capacity and infrastructure to supervise expanded delivery currently mask the ‘true’ costs of scaling up
HIV and syphilis testing in low- and middle-income countries.
• Financing and budgeting for the scale up of HIV and syphilis testing would benefit from the monitoring of costs across
delivery sites over multiple timepoints.
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the provider through a reduction in the number of visits and loss to
follow-up (Mabey et al., 2012; Fleming et al., 2017). Levels of test-
ing may also be lower in less densely populated rural areas while the
costs of delivery (e.g. cost of the test or transport) can be higher
(Shelley et al., 2015).
Currently, decision-makers in LMICs lack a consolidated
evidence base from which to understand the cost implications of
scaling up HIV and syphilis testing. Three reviews of economic stud-
ies evaluating the costs of scaling up of health interventions in
LMICs (Kumaranayake et al., 2001; Johns and Torres, 2005) and
HIV interventions specifically (Kumaranayake, 2008) have been
published, each over a decade old. Each review found evidence of
economies of scale, recommending that future work take scale and
other cost drivers into account when estimating the costs of scaling
up (Kumaranayake et al., 2001; Johns and Torres, 2005;
Kumaranayake, 2008). These reviews also identified best practice
recommendations for measuring economies of scale and the costs of
scaling up public health interventions in LMICs including: ensuring
sufficient and representative sample sizes to capture differences in
cost characteristics across sites; distinguishing between and measur-
ing both fixed and variable costs; and using appropriate analytical
methods, e.g. econometric estimation. None of the reviews capture
the recent proliferation of studies assessing the impact of rapid tests
for HIV and syphilis. In this paper, we systematically review the cur-
rent evidence on the costs of scaling up HIV and syphilis testing in




The review team defined the search terms according to four domains
based on the aims of this review. The four domains included: infec-
tious disease; screening and testing; economics; and LMICs. Despite
the frequent use of the term ‘scaling up’ in international health, in
practice it has been interpreted in many different ways (Mangham
and Hanson, 2010). Search terms relating to ‘scaling up’ were not
included in the initial screening, rather an extensive manual screen-
ing was conducted to filter articles according to the eligibility crite-
ria listed below. The search terms were applied in six databases:
Medline via Ovid; Econlit via Proquest; Embase via Ovid;
EMCARE via EBSCO; CINAHL via EBSCO; and Global Health via
Ovid. The search strategy used medical subject headings for
Medline and comparable terms for the other databases (complete
Medline search terms can be found in Supplementary Appendix S1).
The NHS Economic Evaluation Database, a bibliographic record of
published health technology assessments, was also searched using
the same search strategy. A librarian from the authors institute was
consulted on the search strategy including the selection of domains
and search terms. The systematic review followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (Moher et al., 2009) and is registered on the
International Prospective Register of Systematic Review
(PROSPERO), identification number CRD42018103890.
Eligibility criteria
Studies were eligible for this review if they: (i) measured the costs of
scaling up HIV and/or syphilis testing at scale using empirical data,
modelling or a hybrid of these approaches; (ii) focused on HIV and/
or syphilis testing to identify new infections; (iii) were conducted in
an LMICs, defined according to the World Bank Country and
Lending Groups classification in 2019 (World Bank, 2019); and
(iv) were full research papers (reviews, editorials, letters and confer-
ence papers were excluded). No date or language restrictions were
applied.
Study selection
The search results were imported into an Endnote library and were
independently screened by two reviewers based on their titles and
abstracts. Both reviewers screened the first 10% of articles
(N¼487) against the eligibility criteria to determine the inter-rater
reliability of the reviews. Agreement was assessed using a simple
kappa analysis (McHugh, 2012) and near perfect agreement (kappa
score of 0.96) was achieved and subsequently the screening contin-
ued with a single reviewer (RA) (McHugh, 2012; Wiseman et al.,
2016). Two reviewers read the full text of the selected studies and
any disagreements regarding eligibility were resolved by consulting a
third reviewer. Reasons for exclusion were recorded. Scopus-
Elsevier was used to track the reference lists in the final papers to
identify any additional relevant studies.
Data extraction and appraisal
The variables used to describe the different studies in this review are
shown in Table 1. All data were extracted by two reviewers and all
differences were again resolved by a third reviewer. A narrative syn-
thesis describing the included studies and their conclusions was con-
sidered to be the most appropriate approach to synthesizing the
findings of the studies (Ryan and Cochrane Consumer and
Communication Review Group, 2013). The synthesis from data ex-
traction is presented according to the characteristic of studies
included, type of cost studies undertaken, methods to assess cost and
impact of scale on costs.
The reporting and methodological quality of studies estimating
cost at scale were assessed using a checklist designed for this review
(Table 2). The checklist was developed in consultation with global
experts in the development of existing checklists for costing exer-
cises and include a checklist for good practice in the economic evalu-
ation of health interventions (Husereau et al., 2013); checklists for
appraising priority setting studies in the health sector (Peacock
et al., 2007; Wiseman et al., 2016); Global Health Cost Consortium
guiding principles (Vassall et al., 2017); and best practice guidelines
for calculating the costs of scaling up health interventions (Johns
and Baltussen, 2004; Johns and Torres, 2005; Kumaranayake,
2008). Three reviewers independently appraised the studies against
this checklist, and any disagreements were resolved by consulting
two additional reviewers.
Results
We identified 35 eligible studies from 4869 unique citations as
shown in the PRISMA flow diagram (see Figure 1).
Characteristics of the studies included
Table 3 summarizes the characteristics of 35 included studies in this
review. The majority of studies were conducted in Sub-Saharan
Africa (N¼17), published after 2010 (N¼24) and focused on HIV
testing (N¼33). Only two studies examined the costs of scaling up
syphilis testing (Schackman et al., 2007; Shelley et al., 2015). Most
of the HIV studies involved facility-based testing using rapid tests in
the general adult population (N¼19) or among pregnant women
(N¼6), while all syphilis studies were focused on pregnant women
(N¼2). Only three studies explored the use of HIV self-testing in
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the community and general population (N¼3) (Cambiano et al.,
2015; McCreesh et al., 2017; Mangenah et al., 2019). Four studies
evaluated community-based testing (Tromp et al., 2013; McCreesh
et al., 2017; Cherutich et al., 2018; Mangenah et al., 2019),
only one on home-based testing (Sharma et al., 2016), one on mobile
testing (Verstraaten et al., 2017) and one in the prison (Nelwan
et al., 2016). ‘Scale up’ was most commonly defined in terms of
an increase in population coverage (N¼32) with the remaining
studies defining it as an increase in the number of test kits
distributed (N¼2) or an expansion of a geographical catchment
area (N¼1).
Type of cost studies undertaken
Around half of the studies undertook a cost analysis (N¼17) and an-
other half conducted a cost-effectiveness analysis (CEA) (N¼17)
typically comparing facility-based HIV testing using rapid tests with
laboratory-based testing, with two of those complemented their
Table 1 List of data extraction variables
Study characteristics
Intervention(s) Type of HIV and/or syphilis testing activity or programme
Country Location of study
Study population Group targeted by intervention(s)
Setting Service through which the intervention is delivered (e.g. health centre, hospital) and sector (e.g. public/private)
Time horizon The duration over which costs and/or consequences are calculated
Study design Randomized controlled trial, cross-sectional, cohort, case–control, modelling
Type of economic analysis
(and ratio if applicable)
Cost analysis, cost-effectiveness, cost-utility or cost–benefit analysis. Includes ratio used (e.g. cost per DALY
averted)
Data source(s) Primary data collection, expert/stakeholder opinion, published data or literature or combination of those
Analytical approach to measure
costs at scale
Econometric, empirical, modelling or a hybrid of these approaches (Kumaranayake, 2008)
Costs of scaling up
Definition of scaling up As described by authors
Year (costs) Year of currency values presented (e.g. 2018 dollars)
Unit(s) of output Choice of output measure (e.g. number of clients tested, number of facilities with testing available)
Sample size Total number of, e.g facilities, individuals, tests
Timeframe for decision Short run (fixed inputs cannot be changed) and long run (all inputs can be changed) (Kumaranayake, 2008)
Cost categories Categorization of costs as defined by author(s)
Economies/diseconomies of scale How costs changed with scale of output and by how much.
Empirical results Specific findings related to the costs of scaling up (e.g. coefficients of scale)
Key drivers of costs identified Key drivers of the costs of scaling up (e.g. geography, population sub-group, type of providers)
Table 2 List of appraisal checklist questions
Standard of reporting costs
#1 Was the research question(s) well defined? (Yes/No/Partially addressed)
#2 Was the perspective of the cost estimation clearly stated? (Yes/No/Partially addressed)
#3 Was the time horizon of sufficient length to capture the costs of the intervention at scale? (Yes/No/Partially addressed)
#4 Did the study include relevant inputs in the cost estimation (i.e. consumables, human resour-
ces, equipment and infrastructure, and managerial practice) (Johns and Torres, 2005)?
(Yes/No/Partially addressed)
#5 Were the methods for estimating the quantities of inputs clearly described? (Yes/No/Partially addressed)
#6 Did the study clearly report the selection of data source(s) for the ‘units’ estimated in the cost
per unit?
(Yes/No/Partially addressed)
#7 Was the sample size determined by the precision required for costing? If not, was the sample
designed to be an accurate representation of the study population?
(Yes/No/Partially addressed)
#8 Did the study use relevant and appropriate discount, inflation, and currency conversion rates
to enable cost adjustment over setting and time?
(Yes/No/Partially addressed)
#9 Did the study perform sensitivity analyses to characterize uncertainty associated with cost
estimates?
(Yes/No/Partially addressed)
#10 Were cost estimates reported and communicated in a clear and transparent way? (Yes/No/Partially addressed)
Methodological quality of estimating costs at scale
#11 Were average costs estimated for different levels of scale; and if so, did the study account for
changes in input costs associated with increasing scale of the intervention?
(Yes/No/Partially addressed)
#12 Did the study quantify the relationship between average cost and scale? (Yes/No/Partially addressed)
#13 Were fixed and variable costs analysed separately as scale increased? (Yes/No/Partially addressed)
#14 Were factors other than scale, that could impact on cost, accounted for in the analysis? (e.g.
scope, geography, target population, type of provider)
(Yes/No/Partially addressed)
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CEAs with budget impact analysis (BIA) (Cherutich et al., 2018;
Luong Nguyen et al., 2018). One cost–benefit analysis of HIV testing
in pregnant women was reported (Kumar et al., 2006). Around half
of the studies relied on primary data (N¼18) and the remaining half
used a combination of published evidence and expert opinion
(N¼17). Most studies took a modelling approach to the estimation
of the costs of scaling up testing for HIV and/or syphilis (N¼25).
Methods to assess cost according to scale
Of the 35 eligible studies, 10 measured how costs varied with scale
(see Table 4). All other studies used a constant average cost assump-
tion (i.e. no adjustment for scale) to estimate resource requirements
of scaling up, implicitly assuming that costs were indifferent to scale
and other potential cost drivers. Of the 10 studies measuring the im-
pact of scale on costs, six conducted an econometric analysis by esti-
mating the relationship between cost and cost determinants using
regression analysis and remaining four are empirical studies
(Forsythe, 2002; McConnel et al., 2005; Dandona et al., 2008a,b;
Shelley et al., 2015; Galárraga et al., 2017; Mwenge et al., 2017;
Bautista-Arredondo et al., 2018a; Mangenah et al., 2019).
Impact of scale on costs
The six studies measuring the impact of scale on costs found that the
average cost per person tested (most commonly for HIV using a
rapid test) decreased as scale increased, demonstrating that
economies of scale were possible (i.e. confirmed through a negative
coefficient on the scale variable), with coefficient of scale is ranging
from 0.18 to 0.83 (Dandona et al., 2005; McConnel et al., 2005;
Galárraga et al., 2017; Mwenge et al., 2017; Bautista-Arredondo
et al., 2018b; Mangenah et al., 2019). The main driver of these
economies of scale is the distribution of fixed cost to a larger num-
ber of patients or outputs. The remaining four studies took an
empirical-based approach whereby the relationship between scale
and cost was based on observations of the actual cost at different
levels of scale (Forsythe, 2002; McConnel et al., 2005; Dandona
et al., 2008a,b; Shelley et al., 2015). Three of the four studies
showed that the costs of screening per person decreased as scale
increased (Forsythe, 2002; McConnel et al., 2005; Dandona et al.,
2008a,b). One empirical study reported an increase in the average
cost per client tested as the intervention was rolled out to new sites,
which was attributed to several factors including higher rapid point-
of-care syphilis tests prices and lower rapid syphilis testing (RST)
uptake in the targeted population (Shelley et al., 2015).
Fixed vs variable costs
All studies in this review were based on a short-run decision frame-
work, during which the amount of fixed inputs could not be easily
varied. The costs of scaling up HIV and syphilis testing tended to be
narrowly defined as the cost of the test, personnel and associated
consumables such as gloves and cotton swabs (N¼18). Only 10 out
Figure 1 PRISMA flow diagram
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of 35 included studies separated the fixed and variable component
of costs. A small number of studies (N¼8) attempted to include
more cost items such as the costs of educational materials, monitor-
ing and supervision or waste management. Few studies (N¼4) con-
sidered the costs of managing the scaling up process including the
costs of quality management and investment in procuring new
equipment. In addition to scale, other key drivers of cost included
availability of transport infrastructure, variation in the price of local
goods (e.g. test kits, medicines, fuel), costs and frequency of super-
visory trips and the recruitment and training of health personnel, es-
pecially in remote areas.
Quality of studies included
Table 5 summarizes the results of the appraisal. Most studies clearly
reported the research question(s), perspective taken and the time
horizon for the analysis (N¼29). No study justified their sample
size for the costing and around half undertook a sensitivity analysis
for major cost inputs (N¼19). There were widespread gaps in the
methodological quality of estimating costs at scale. Specifically, less
than half of the studies in this review estimated average costs at dif-
ferent levels of scale (N¼6), measured the relationship between
average costs and scale (N¼9) or separated fixed and variable costs
(N¼10), which are all necessary to accurately measure economies
or diseconomies of scale (Kumaranayake, 2008).
Discussion
To expand access to HIV and syphilis testing and reach elimination
targets, successful small-scale programmes need to cover broader
populations in LMICs. The availability of reliable and detailed in-
formation on the resources required to do this is a key determinant
of success (Johns and Torres, 2005; Kumaranayake, 2008; World
Health Organization and ExpandNet, 2009; Mangham and
Hanson, 2010). This review validates that scale is an important
driver in determining the costs of HIV and syphilis testing pro-
grammes in resource-constrained health systems. It also reveals the
potential for economies of scale (i.e. a reduction in average costs as
the number of people tested increases) at least in the short run when
structural changes to health systems (e.g. training, quality manage-
ment and stock management) necessary for the large scale delivery
of testing have not yet been undertaken.
Despite syphilis testing being widely recommended for use in
LMICs, particularly in pregnancy (Newman et al., 2013; Storey
et al., 2019), only two studies explored the costs of scaling up syph-
ilis testing. Recent pilot studies have demonstrated the cost-
effectiveness of HIV and syphilis screening using a dual rapid test
over single HIV and syphilis tests or HIV testing alone (Bristow
et al., 2016). It has been argued that dual tests for HIV and syphilis
may potentially contribute to economies of scale and scope (associ-
ate with the sharing of fixed costs across activities) in terms of start-
up, training, quality management, supervision and monitoring while
also serving to promote syphilis testing, which is lagging well behind
HIV testing in many LMICs (Bristow et al., 2016; Taylor et al.,
2017). While there were many studies that found community-based
strategies are effective in increasing uptake of testing (Asiimwe
et al., 2017; Ahmed et al., 2018), this review revealed a lack of at-
tention paid to the economic impact of scaling up these strategies.
Many key populations have expressed a strong preference for
community-based testing, which is seen as less stigmatizing and
more accessible (Suthar et al., 2013). Despite the growing import-
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LMICs (Rao et al., 2011; Wang et al., 2017), only one study explor-
ing the costs of scaling up the delivery of testing through private or
non-government providers (Verstraaten et al., 2017) was identified.
Further research on the costs of scaling up syphilis testing and mod-
elling community-based HIV and syphilis testing in public and pri-
vate sectors are needed.
Our review highlighted that while the overall standard of report-
ing costs was reasonable, with most studies partially or fully
addressing seven or more of the ten questions, shortcomings mani-
fested in two key areas. First, none of the studies in this review justi-
fied their sample size for the costing. Economic evaluations often
require larger sample sizes for adequate power compared to a typical
clinical study evaluating the health impact of a testing intervention
(Taylor et al., 2017). However, clinical studies and economic evalu-
ations generally investigate differences in outcomes at the individual
level. Cost drivers, such as scale, are better identified through multi-
site cost studies with the production unit or clinic as the unit of ana-
lysis (Tagar et al., 2014). A representative sample should capture
differences in clinic characteristics such as geographical setting,
ownership, and management systems. However, commonly the trial
sample size or convenience sampling, in a limited number of sites,
determines sample size for a full or partial economic evaluation.
Given the considerable uncertainties around the costs of going to
scale including the varying cost of procuring and delivering test kits
(Johns and Torres, 2005; Shelley et al., 2015), it was surprising that
almost half of the studies failed to explore the influence of different
key inputs on unit costs or total programme costs by conducting sen-
sitivity analysis. For example, volume purchasing, which is being
explored in many LMICs, is likely to impact the cost and uptake of
rapid diagnostic tests (Taylor et al., 2017) and worth closer
consideration.
From a methodological viewpoint, the appraisal revealed that
only eight studies adjusted for changes in unit costs as HIV and
syphilis testing was scaled up (McConnel et al., 2005; Dandona
et al., 2008a,b; Shelley et al., 2015; Galárraga et al., 2017; Mwenge
et al., 2017; Bautista-Arredondo et al., 2018a; Mangenah et al.,
2019). Scaling up HIV and syphilis testing programmes typically
involves transporting supplies longer distances and to more remote
areas compared to pilot programs, which can lead to variations in
the prices of consumables such as testing kits. The impact on pro-
gramme outcomes must also be considered alongside any changes in
costs. Sweeney et al. (2014) have argued that, while devolving super-
vision and monitoring of RST in Tanzania to authorities at the sub-
national level may lead to reductions in the frequency and cost of ex-
ternal quality assurance, this may pose challenges for quality main-
tenance (Sweeney et al., 2014) . Our appraisal also revealed that
despite majority (22 out of 35) of studies have clearly stated their
perspective, only three of these adopted a societal perspective. This
means that a significant proportion of direct and indirect cost
incurred by patients for accessing tests is not considered. Moreover,
while most studies included a range of recurrent costs (e.g. staff
time, training, testing commodities and other medical supplies) and
capital costs (e.g. vehicles and computers) and were focused at the
level of a clinic or health centre, few acknowledged the required
investments in infrastructure (e.g. quality management, reporting
system) and broader health systems strengthening needed as HIV
and syphilis testing programmes are scaled up to the national level
across all clinics and facilities (Kumaranayake et al., 2001). These
‘higher level’ investments refer ‘to the policy, political, legal, regula-
tory, budgetary or other health systems changes needed to institu-
tionalize new innovations at the national or sub-national level’
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Another area for methodological improvement relates to the
quantification of the relationship between average costs and the
scale of delivering HIV or syphilis testing. Most studies undertook a
simple form of modelling whereby costs were scaled up linearly. For
these studies, an empirical average cost associated with a testing
programme was multiplied by a factor representing activity at a
larger scale. For example, if the unit cost per person tested for HIV
and syphilis is United States Dollar (USD) 10 for 100 people then
expanding coverage by another 50 people would be USD 500
(Kumaranayake, 2008). Only 10 of the 35 studies developed non-
linear cost functions, allowing some costs to be fixed regardless of
the size of the population reached—e.g. medical equipment, vehicles
or buildings—leading to economies of scale. For one study on the
roll out of syphilis rapid testing in Zambia, lower clinic catchment
populations combined with higher unit costs for transport, supervi-
sion and test kits reduced the economies of scale achieved in the
high coverage pilot sites (Shelley et al., 2015). This resonates with
economic theory as output increases average costs will first fall and
then rise, following a ‘u’-shaped curve (Guinness, Kumaranayake
and Hanson, 2007; Kumaranayake, 2008). This small subset of
studies represents an important step forward in providing a more ac-
curate estimation of the costs of scaling up HIV and syphilis testing
interventions in LMICs, painting a more complex picture of the rela-
tionship between scale and costs.
Table 5 Results of the appraisal



































































































































































Shelley et al. (2015)   ()   X ()    ()   
Schackman et al. (2007)   X ()   X ()   () X X 
Bautista-Arredondo et al. (2018a,b)       () () X     
Dandona et al. (2008a,b)  ()     ()  X  () X  X
Galárraga et al. (2017)  X     ()  X     
Hontelez et al. (2013)    () () () ()   () () X X X
Ishikawa et al. (2016)   () () X  X ()  () X X X ()
McConnel et al. (2005)  X     X () X   X  X
Ahaibwe G & Kasirye I (2013)  X  X X X () ()  () X X X X
Alsallaq et al. (2017)   () () ()  () ()   X X X X
Cambiano et al. (2015)   () () ()  X ()  () X X X ()
Cherutich et al. (2018)       () ()   () X () 
Mwenge et al. (2017)       ()       
Stuart et al. (2018)  X () () () () X X X () () X X ()
Tromp et al. (2013)    ()  () () ()  () X X () 
Zhuang et al. (2018)    () () X X  X () () X X X
Dandona et al. (2008a,b)  ()     ()  X     
Dandona et al. (2005)  X     ()  X () ()   
Forsythe (2002)    ()   X () X  X   
Granich et al. (2009)  X () () () () X X X () X X X X
Kasymova et al. (2009)       ()  X  () X () X
Kato et al. (2013)  X  () X  () () X  () X X 
Kumar et al. (2006)   () () () () X   () () X X 
Dandona et al. (2009)  ()     ()   () () X () 
Mangenah et al. (2019)       ()       X
McCreesh et al. (2017)    () X  () ()  () X X X 
Minh et al. (2012)    ()   ()  X  X X () X
Sharma et al. (2016)      () ()    () X () ()
Nelwan et al. (2016)    () X () X X X () X X X X
Luong Nguyen et al. (2018)  ()   ()  ()    X X () X
Rely. (2003)   () () X () X ()  () X X X ()
Tchuenche et al. (2018)  ()     ()  ()  X X X 
Verstraaten et al. (2017)      () () ()   X X () X
Zang et al. (2016)    () ()  ()   () () X X ()
Zhang et al. (2015)  ()     () () X  ()  () 
: yes; X: no; (): partially addressed.
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There are some limitations of this review that need to be
acknowledged. Studies were restricted to those found in the pub-
lished literature, a potential source of reporting bias. In addition, the
studies identified varied by analytical approach (empirical, econo-
metric or model), testing intervention and types of costs measured.
This diversity prevented the pooling of results for a meta-analysis.
Instead, studies were qualitatively reviewed, and their results and
characteristics tabulated which helped to highlight evidence gaps
and methodological weaknesses.
In summary, this review highlights evidence of the relationship
between the costs and scale of delivering HIV and syphilis testing in
LMICs. What is less clear is how costs change with scale and in turn
the potential for economies of scale. Scaling up costs linearly, an as-
sumption that underpins most studies in this review, and runs the
risk of misleading policymakers as to the true costs of providing uni-
versal access to HIV and syphilis testing. Collecting empirical cost
data alongside the roll-out of HIV and syphilis testing is a priority.
Financing and budgeting for the scale up of HIV and syphilis testing
will benefit from the monitoring of costs across different sites, con-
texts and settings as well as over time, for greater consistency in the
categorization of fixed and variables costs, and the inclusion of costs
associated with strengthening health systems to support quality as-
surance and stock management systems.
Supplementary data
Supplementary data are available at Health Policy and Planning online
Acknowledgements
The authors thank Monica O’Brien, the UNSW Academic Services Librarian;
Fern Terris-Prestholt, Associate Professor in Economics of HIV, London
School of Hygiene and Tropical Medicine (LSHTM); Anna Vassal, Professor
of Health Economics, London School of Hygiene and Tropical Medicine; and
Benjamin Johns, Abt Associates, International Health Division, Bethesda,
USA.
Funding
Corresponding author has received funding from the Scientia PhD
Scholarship scheme provided by the University of New South Wales.
Conflict of interest statement. None declared.
Ethical approval. No ethical approval was required for this study
References
Ahaibwe G, Kasirye I. 2013. HIV/AIDS prevention interventions in Uganda: a
policy simulation. Research Series 167527, Economic Policy Research
Centre (EPRC).
Ahmed S, Autrey J, Katz IT et al. 2018. Why do people living with HIV not ini-
tiate treatment? A systematic review of qualitative evidence from low- and
middle-income countries. Social Science & Medicine 213: 72–84.
Alsallaq RA, Buttolph J, Cleland CM et al. 2017. The potential impact and
cost of focusing HIV prevention on young women and men: a modeling ana-
lysis in western Kenya. PLoS One 12: e0175447.
Asiimwe S, Ross JM, Arinaitwe A et al. 2017. Expanding HIV testing and link-
age to care in southwestern Uganda with community health extension work-
ers. Journal of the International AIDS Society 20(Suppl 4): 21633.
Bautista-Arredondo S, La Hera-Fuentes G, Contreras-Loya D et al. 2018a.
Efficiency of HIV services in Nigeria: determinants of unit cost variation of
HIV counseling and testing and prevention of mother-to-child transmission
interventions. PLoS One 13(9): e0201706.
Bautista-Arredondo S, Colchero MA, Amanze OO et al. 2018b. Explaining
the heterogeneity in average costs per HIV/AIDS patient in Nigeria: the role
of supply-side and service delivery characteristics. PLoS One 13(5):
e0194305.
Bert F, Gualano MR, Biancone P et al. 2018. HIV screening in pregnant
women: a systematic review of cost-effectiveness studies. The International
Journal of Health Planning and Management 33: 31–50.
Bristow CC, Larson E, Anderson LJ et al. 2016. Cost-effectiveness of HIV and
syphilis antenatal screening: a modelling study. Sexually Transmitted
Infections 92: 340–6.
Cambiano V, Ford D, Mabugu T et al. 2015. Assessment of the potential im-
pact and cost-effectiveness of self-testing for HIV in low-income countries.
Journal of Infectious Diseases 212: 570–7.
Cherutich P, Farquhar C, Wamuti B et al.; for the aPS Study Group. 2018.
HIV partner services in Kenya: a cost and budget impact analysis study.
BMC Health Services Research 18: 721.
Dandona L, Sisodia P, Ramesh YK et al. 2005. Cost and efficiency of HIV vol-
untary counselling and testing centres in Andhra Pradesh, India. The
National Medical Journal of India 18: 26–31.
Dandona L, Kumar SP, Ramesh YK et al. 2008a. Changing cost of HIV inter-
ventions in the context of scaling-up in India. AIDS 22: S43–9.
Dandona L, Kumar SP, Ramesh YK et al. 2008b. Outputs, cost and efficiency
of public sector centres for prevention of mother to child transmission of
HIV in Andhra Pradesh, India. BMC Health Services Research 8: 26.
Dandona L, Kumar SP, Kumar GA et al.Economic analysis of HIV prevention
interventions in Andhra Pradesh state of India to inform resource allocation.
AIDS 23: 233–42. 10.1097/QAD.0b013e328320accc
Fleming K A, Naidoo M, Wilson M et al.. 2017. An Essential Pathology
Package for Low- and Middle-Income Countries. American Journal of
Clinical Pathology 147: 15–32. 10.1093/ajcp/aqw143 28158414
Forsythe S. 2002. Assessing the cost and willingness to pay for voluntary HIV
counselling and testing in Kenya. Health Policy and Planning 17: 187–95.
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